2022 Spring Newsletter

2022 Spring Newsletter

It’s been a busy Spring conference season. Read more about our data and presentations below. We have access to more than 80% of the US healthcare system with patient-level data across all-provider types. See how we support evidence generation needs and let us...
Effectiveness and safety of apixaban versus warfarin in obese patients with nonvalvular atrial fibrillation enrolled in Medicare and Veteran Affairs

Increased comorbidity burden among HDV infection vs HBV mono-infection among commercially insured adults in the United States: An All-Payer Claims Database analysis

Abstract BACKGROUND: Hepatitis delta is caused by a defective RNA virus (HDV) that requires the presence of hepatitis B surface antigen for replication and transmission. Compared to hepatitis B virus (HBV) monoinfection, patients with HDV have a greater risk of...
Effectiveness and safety of apixaban versus warfarin in obese patients with nonvalvular atrial fibrillation enrolled in Medicare and Veteran Affairs

Hepatitis delta among commercially-insured patients in the United States: An analysis of prevalence, patient characteristics and socioeconomic status

Abstract BACKGROUND: Hepatitis delta virus (HDV) requires hepatitis B virus (HBV) for its replication. HDV infection leads to the most severe form of viral hepatitis, which is associated with an increased risk of liver-related morbidity and mortality. HDV prevalence...